On November 20, 2020 Grey Wolf Therapeutics reported at both the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting and the Neoantigen Based Therapies Summit (Press release, Grey Wolf Therapeutics, NOV 20, 2020, View Source [SID1234571457]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Neoantigen Based Therapies Summit took place between 3-5th November 2020. Dr. Peter Joyce, CEO & Co-founder of Grey Wolf Therapeutics, presented the data that has led to the nomination of a candidate, first-in-class ERAP1 inhibitor that is currently progressing through non-clinical development. Starting with ERAP1 inhibition as a concept, Dr. Joyce explained how Grey Wolf has been able to prove out the four corners of ERAP1 biology; target engagement, antigen modulation, T-cell response and tumour growth inhibition.

In October, Grey Wolf was delighted to find out that their abstract had been selected for an oral presentation at SITC (Free SITC Whitepaper) 2020 (10-15th November). The presentation formed part of the Combinatorial Therapies session, chaired by Charlotte E. Ariyan, MD, PhD (Memorial Sloan Kettering Cancer Center) and Silvia Formenti, MD (Weill Cornell Medicine) on Wednesday 11th November. The team presented new data which demonstrates that ERAP1 inhibition has the potential to be a transformative therapeutic agent that could be used as monotherapy or in combination with other immunotherapies such as checkpoint blockade.